Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426268 · ClinicalTrials.gov registry record
FORE-SIGHT Tissue Oximeter During Cardiac Surgery
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 55
- Enrollment target
NCT02426268: Completed study, sponsored by University of California, Los Angeles.
NCT02426268 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02426268 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to measure cerebral and lower extremity oximetry on patients during cardiac surgery.
Primary Outcome
Two sensors from FORE-SIGHT Elite monitor will be placed on the forehead above the eyebrows to continuously monitor cerebral oxygen saturation.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-11-21 |
What the finished NCT02426268 record still lists
NCT02426268 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02426268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02426268 about?
NCT02426268 is a clinical study titled "FORE-SIGHT Tissue Oximeter During Cardiac Surgery". The purpose of this study is to measure cerebral and lower extremity oximetry on patients during cardiac surgery.
What is the current status of trial NCT02426268?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2014-05. Estimated completion is 2019-11-21.
Who is sponsoring clinical trial NCT02426268?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia